Literature DB >> 10535654

Subtyping depression: testing algorithms and identification of a tiered model.

G Parker1, K Wilhelm, P Mitchell, K Roy, D Hadzi-Pavlovic.   

Abstract

We seek to distinguish psychotic, melancholic, and nonmelancholic depression by clinical features and to test varying algorithm models to determine optimal criteria sets. We report a study of 269 depressed inpatients and outpatients. A latent class analysis (LCA) of 16 clinical features allowed for specificity or overrepresentation of features to be examined across the three classes. Varying algorithm models for distinguishing melancholic and nonmelancholic depression, involving endogeneity symptoms and observer-rated psychomotor disturbance (PMD) were compared. Psychotic depression was readily distinguished by the specific presence of psychotic features, and PMD was most severe in this class. Melancholic depression was most clearly distinguished from the residual nonmelancholic class by the presence of PMD. Although some endogeneity symptoms were overrepresented in the melancholic class, their specificity was unimpressive. An algorithm involving PMD components alone was highly efficient in discriminating LCA classes and, more importantly, superior to DSM-IV decision rules when examined against a range of clinical validators of melancholia. Subtyping appears assisted by a hierarchical model, based on a small set of features. The move from nonmelancholic to melancholic depression appears defined by a tier of observably rated PMD, whereas the move from melancholic to psychotic depression is determined by a tier of psychotic features and contributed to by significantly higher levels of PMD.

Entities:  

Mesh:

Year:  1999        PMID: 10535654     DOI: 10.1097/00005053-199910000-00004

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  6 in total

1.  Defining a comprehensive verotype using electronic health records for personalized medicine.

Authors:  Mary Regina Boland; George Hripcsak; Yufeng Shen; Wendy K Chung; Chunhua Weng
Journal:  J Am Med Inform Assoc       Date:  2013-09-03       Impact factor: 4.497

2.  Subtypes of major depression: latent class analysis in depressed Han Chinese women.

Authors:  Y Li; S Aggen; S Shi; J Gao; Y Li; M Tao; K Zhang; X Wang; C Gao; L Yang; Y Liu; K Li; J Shi; G Wang; L Liu; J Zhang; B Du; G Jiang; J Shen; Z Zhang; W Liang; J Sun; J Hu; T Liu; X Wang; G Miao; H Meng; Y Li; C Hu; Y Li; G Huang; G Li; B Ha; H Deng; Q Mei; H Zhong; S Gao; H Sang; Y Zhang; X Fang; F Yu; D Yang; T Liu; Y Chen; X Hong; W Wu; G Chen; M Cai; Y Song; J Pan; J Dong; R Pan; W Zhang; Z Shen; Z Liu; D Gu; X Wang; X Liu; Q Zhang; J Flint; K S Kendler
Journal:  Psychol Med       Date:  2014-04-09       Impact factor: 7.723

3.  Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression.

Authors:  Arpana Agrawal; Elliot C Nelson; Andrew K Littlefield; Kathleen K Bucholz; Louisa Degenhardt; Anjali K Henders; Pamela A F Madden; Nicholas G Martin; Grant W Montgomery; Michele L Pergadia; Kenneth J Sher; Andrew C Heath; Michael T Lynskey
Journal:  Arch Gen Psychiatry       Date:  2012-07

4.  Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.

Authors:  R Uher; R H Perlis; N Henigsberg; A Zobel; M Rietschel; O Mors; J Hauser; M Z Dernovsek; D Souery; M Bajs; W Maier; K J Aitchison; A Farmer; P McGuffin
Journal:  Psychol Med       Date:  2011-09-20       Impact factor: 7.723

5.  Increased plasma norepinephrine concentration in psychotic depression.

Authors:  Jaap G Goekoop; Remco F P de Winter; Ron Wolterbeek; Godfried M J Van Kempen; Victor M Wiegant
Journal:  Ther Adv Psychopharmacol       Date:  2012-04

Review 6.  Data-driven subtypes of major depressive disorder: a systematic review.

Authors:  Hanna M van Loo; Peter de Jonge; Jan-Willem Romeijn; Ronald C Kessler; Robert A Schoevers
Journal:  BMC Med       Date:  2012-12-04       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.